The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC [Mesenchymal stem cells] transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days.

The intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.

Source: https://www.nationalreview.com/corner/covid-19-adult-stem-cell-trials/

Translate »